PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells

Janelle Sharkey,1 Tiffany Khong,1 and Andrew Spencer1

1Myeloma Research Group, The Alfred Hospital, Melbourne, Victoria, Australia

The effect and mode of action of the protein kinase C (PKC) inhibitor PKC412 on human multiple myeloma (MM) cell lines (HMCLs) and primary MM cells was explored. We found that PKC412 induced apoptosis of HMCLs and primary MM cells with variable efficacy; however, some activity was seen against all HMCLs and primary MM cells with at least 0.5 μM PKC412. PARP cleavage and decreased PKC activity was observed in all HMCLs tested. Furthermore, PKC412 inhibited C-FOS transcription and nuclear protein expression, induced reactive oxygen species (ROS) production, and induced both sustained C-JUN expression and phosphorylation. The latter was inhibited by cotreatment with the JNK inhibitor SP600125, which similarly abrogated PKC412-induced apoptosis, suggesting that PKC412-induced apoptosis is a JNK-dependent event. PKC412 treatment secondarily induced prosurvival stress responses as evidenced by activation of NFκB and increased expression of the heat shock proteins HSP70 and HSP90.

Consistent with the former, sequential inhibition of NFκB activation with bortezomib or SN50 synergistically enhanced cell killing. Our results demonstrate that PKC412 induces JNK-dependent apoptosis of HMCLs and primary MM cells and that this effect is enhanced by NFκB inhibition. The further evaluation of PKC412 in the treatment of MM is justified. (Blood. 2007;109:1712-1719)

Introduction

Multiple myeloma (MM) is a B-cell malignancy, which occurs predominantly at an older age and is still incurable despite progress in treatment.1 The investigation of novel anticancer drugs for the treatment of this disease is therefore warranted. Protein kinase C (PKC) is a phospholipid-dependent, serine/threonine kinase responsible for signal transduction in response to growth factors, hormones, and neurotransmitters.2 PKC plays an important role in cell-growth regulation and tumor promotion3 and has also been implicated in metastasis4 and chemotherapy-associated multidrug resistance.5 Total PKC activity has been reported to be elevated in carcinomas of breast6 and lung.7 In MM, PKC has been implicated in the shedding of CD1388 and the IL-6 receptor,9 both of which are thought to play important roles in tumor progression. Eleven isoforms of PKC have been identified, and these have been separated into 3 subgroups: (1) the conventional calcium-dependent and DAG (diacylglycerol)–dependent PKCs (cPKCs: α, β, βII, γ), (2) the nonconventional calcium-independent but DAG-dependent PKCs (nPKCs: δ, ε, η, μ, ζ, λ), and (3) the atypical calcium-independent and DAG-unresponsive PKCs (aPKCs: ξ, ι).

The PKC inhibitor PKC412 (N-benzylstaurosporine) is a derivative of the naturally occurring alkaloid staurosporine and has been shown to inhibit the conventional isoforms of PKC (α, β, βII, γ). PKC412 has been shown to have an antitumor effect on human non–small-cell lung cancer cells10 and myeloma cells11,12 and has also been shown to inhibit growth factor–dependent C-FOS mRNA expression.13 PKC412 has also shown antitumor activity in a murine model of myeloproliferative disease14 as well as in an FGFR3 TDII–induced murine model of B-cell lymphoma.15

The AP-1 transcription factor consists of homodimers of Jun proteins or heterodimers of Fos and Jun proteins15,16 and plays a key role in the regulation of expression of genes involved in DNA repair, cell proliferation, cell-cycle arrest, death by apoptosis, and tissue and extracellular matrix remodeling proteases.17 Formation of AP-1 dimers requires activation by phosphorylation of c-Jun18; thus, c-Jun and AP-1 activities are regulated by c-Jun N-terminal phosphorylation through Jun N-terminal kinases (JNKs).19 JNK belongs to the mitogen-activated protein kinase family19 and has a known role in both drug20 and stress-induced apoptosis.21 C-FOS is an immediate early response gene that can be induced following activation of specific growth factor receptors13 and is known to have a role in cell proliferation, differentiation, and transformation.22

In the present study, we show that PKC412 induces apoptosis of HMCLs and primary MM cells and that this is, in part, mediated by c-jun activation by JNK. Furthermore, by sequentially blocking the PKC412-induced secondary prosurvival stress response, enhanced tumor-cell killing can be achieved.

Materials and methods

Cell culture

The human myeloma cell lines (HMCLs) U266, RPMI-8226, NCI-H929, and LP-1 were obtained from the American Type Culture Collection (Rockville, MD). KMS-11 was a kind gift from Dr Takemi Otsuki from the Kawasaki Medical School, Kawasaki, Japan, and OPM2 was purchased from an anonymous donor.
from the German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany). These HMCs were cultured in our laboratory in RPMI 1640 (JRH Biosciences, Brooklyn, VIC, Australia) with 10% iron-fortified fetal bovine serum (IF FBS) (JRH Biosciences), 50 U/mL penicillin, 50 g/mL streptomycin, and 2.9 g/mL L-glutamine (Invitrogen, Mount Waverley, VIC, Australia) (Complete RPMI). Cells were incubated at 37°C in 5% carbon dioxide.

Mononuclear cells (MNCs) were isolated from the bone marrow (BM) samples of patients with MM after obtaining informed consent. Bone marrow was spun at 500g for 10 minutes to pellet cells, and plasma was collected. Pelleted cells were then resuspended in Iscove modification of Dulbecco medium (IMDM; JRH Biosciences) to 3 times the original sample volume, and DNase I was added to a final concentration of 1 g/mL. The sample was then incubated for 30 minutes at room temperature, rolling. Ficol-Hypaque Plus solution (Amersham Biosciences, Castle Hill, NSW, Australia) was layered under the BM sample so that the volume of Ficol solution was approximately one third the total volume in the tube. The BM sample was then spun at 800g for 25 minutes, and MNCs were collected from the Ficol/IMDM interface. Red blood cells (RBCs) were lysed by incubation with RBC lysis buffer (8.29 g/L ammonium chloride, 0.037 g/L EDTA, 1 g/L potassium bicarbonate) for 5 minutes at 37°C. MNCs were washed twice with sterile PBS and resuspended in complete RPMI and treated with PKC412 and/or bortezomib.

Reagents
PKC412 was kindly supplied by Novartis (Basel, Switzerland). It was dissolved in dimethyl sulfoxide (DMSO), stored at −20°C, and tested at 0.1 to 20 g/L in the presence of culture medium with 10% IF FBS. Bortezomib was purchased from Janssen-Cilag (North Ryde, NSW, Australia), dissolved in 0.9% saline, and used at 8 nM. The JNK inhibitor SP600125 (Calbiochem, San Diego, CA) was dissolved in methanol and used at a final concentration of 1 g/mL. I-N-acetylcycteine (L-NAC) (Calbiochem) was dissolved in sterile water and used at a final concentration of 15 mM.

MTS assay
U266, LP-1, KMS-11, NCI-H929, OPM2, and RPMI-8226 cells (0.25 × 10^6/mL) were incubated with various concentrations of PKC412 (0.1-20 μM) for 24 and 72 hours in 96-well plates (Sarstedt, Ingle Farm, SA, Australia). After culture, cell number and viability were determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H- tetrazolium (MTS) assay (Pierce Biotechnology, Rockford, IL). Synergistic drug effects were quantified by calculation of the Synergism quotient (SQ). The SQ is the net effect of the combination [drug A + drug B] divided by the sum of the net individual effect [A] + [B]. An SQ greater than 1 indicates a synergistic effect.

Assessment of apoptosis
To examine apoptotic-cell death, NCI-H929 and LP-1 cells were treated for 72 hours with (experiment 1) 4 μM PKC412, 25 μM SP600125, or both (SP600125 added 30 minutes prior to PKC412) or (experiment 2) 1 and 3 μM PKC412 and stained for flow cytomtery with annexin V–FITC (BioSource, Camarillo, CA) and propidium iodide (Sigma, NSW, Australia). Cells were washed once in 2 mL annexin V binding buffer (0.01 M HEPES, 0.14 M NaCl, 2.5 mM CaCl_2, pH 7.4) and resuspended in 100 μL of this buffer, to which 1 μL annexin V–FITC was added. Cells were incubated in the dark for 15 minutes then washed once with 2 mL AB buffer. Cells were then resuspended in 300 μL AB buffer with 18.75 ng propidium iodide and analyzed by flow cytomtery (Becton Dickinson FACScan; BD Biosciences, San Jose, CA). Data were analyzed using Expo 32 software (Beckman Coulter, Gladesville, NSW, Australia).

Assessment of primary myeloma-cell death
BM MNCs isolated from patients with MM were treated with PKC412 and/or bortezomib for 72 hours and were harvested for analysis by flow cytomtery. Cells were washed in PBS, then resuspended in 100 μL PBS, and incubated for 10 minutes with Intragram P (1:50) (CSL Biosciences, Parkville, VIC, Australia). Anti-human CD138 FITC-conjugated antibody (BD Biosciences) and anti-human CD38 PE-conjugated antibody (BD Biosciences) were then added at 1:20 dilution, and cells were incubated in the dark for 15 minutes. Cells were then washed twice with 2 mL PBS and resuspended in 200 μL PBS with propidium iodide (PI) at 0.0625 μg/mL and analyzed by flow cytomtery (Becton Dickinson FACScan, BD Biosciences) to identify CD38+/CD138+/PI+ or CD38+/CD138+/PI cells. Data were analyzed using Expo 32 software (Beckman Coulter).

Protein kinase C functional assay
PKC activity after 24 and 72 hours of treatment with 5 μM PKC412 was determined using the PepTag assay for nonradioactive detection of PKC (Promega, Madison, WI) according to the manufacturer’s directions. Briefly, this assay uses a brightly colored, fluorescent peptide substrate that is highly specific for PKC. Phosphorylation by PKC of the specific peptide substrate alters the peptide’s net charge from +1 to −1. This change in the net charge of the substrate allows the phosphorylated and nonphosphorylated versions of the substrate to be rapidly separated on a 1% agarose gel. The phosphorylated peptide migrates toward the positive electrode, whereas the nonphosphorylated peptide migrates toward the negative electrode. The gel is then photographed using UV illumination, and the amount of phosphorylated peptide (proportional to the amount of functional PKC) is determined by densitometry.

Reverse transcriptase–polymerase chain reaction (RT-PCR)
RNA was extracted from cells using the RNeasy RNA extraction kit (Qiagen, Doncaster, VIC, Australia) and cDNA synthesized using the Sensiscript RT kit (Qiagen) following the manufacturer’s directions. C-FOS and β-ACTIN PCRs were performed using the following cycling conditions: 95°C 2 minutes (1 cycle); 95°C 1 minutes, 60°C 1 minute, 72°C 1 minute (30 cycles); 72°C 7 minutes (1 cycle). Primers were as follows: C-FOS downstream, TGA GAA GAG GCA GGG TAG AGG, and C-FOS upstream, CCG AAG GGA AAG GAA TAA GAT. β-ACTIN reverse, CAG CCG AAC CGC GTA TGG CCA ATG G, and β-ACTIN forward, TCA CCC ACA CTC TGC CCA TCT ACG TA. C-JUN PCR was performed using the following cycling conditions: 94°C 5 minutes (1 cycle); 94°C 30 seconds, 60°C 30 seconds, 72°C 1 minute (35 cycles); 72°C 10 minutes (1 cycle). Primers were as follows: C-JUN forward, AAA AGT GAA AAG CTT GAA AGC TCA G, and C-JUN reverse, CGT GGT TCA TCT GTT CTT TGA TAA G. PCR products were visualized using a 2% agarose gel. In all cases, equivalent quantities of cDNA template were used, and results were adjusted for variations in PCR efficiency by normalization to β-ACTIN.

Western blot analysis
After treatment cells were washed once with cold PBS and lysates were prepared using either NE PER nuclear and cytoplasmic extraction kit (Pierce Biotechnology) following the manufacturer’s directions or RIPA buffer (10 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% vol/vol Triton X-100, 1% wt/vol sodium deoxycholate, 0.1% wt/vol SDS, 2 mM sodium vanadate, 10 mM sodium fluoride, 1 mM PMSF, complete EDTA protease inhibitor cocktail [Roche, NSW, Australia]). Proteins were resolved on 7% or 10% SDS polyacrylamide gels and transferred to a Hybond-C nitrocellulose membrane (Amersham, Arlington Heights, IL). Membranes were probed with antibodies where appropriate. Anti-c-Jun (Santa Cruz Biotechnology, Santa Cruz, CA), -p-c-Jun (Santa Cruz Biotechnology), -c-Fos (Santa Cruz Biotechnology), -PARP (Santa Cruz Biotechnology), -PKCα (Santa Cruz Biotechnology), -PKCβ (Santa Cruz Biotechnology), -PKCβ (Santa Cruz Biotechnology), -PKCγ (Santa Cruz Biotechnology), -p21 (Santa Cruz Biotechnology).
-p53 (Cell Signaling Technologies, Beverly, MA) and -α-tubulin (Sigma) antibodies were used to probe membranes. The blots were developed using the Supersignal west pico or dura chemiluminescent reagents (Pierce Biotechnology).

**Results**

**PKC412 induces apoptosis of HMCLs and primary MM cells**

HMCLs were treated with PKC412 for 24 to 72 hours with a decrease in cell proliferation seen at doses of at least 0.5 μM (Figure 1A). Following 72 hours of 5 μM PKC412 the 4 HMCLs (OPM2, NCI-H929, KMS-11, and RPMI-8226) harboring activating mutations of either RAS or FGFR3 (Ras/FGFR3-positive) were clearly more sensitive than the HMCLs (U266 and LP-1) without either activating mutation (Ras/FGFR3-negative) (Figure 1A) with the difference between each individual Ras/FGFR3-positive HMCL versus each negative HMCL being statistically significant (range, \( P = .019 \) to \( P < .001 \), Student \( t \) test) (see legend to Figure 1A). Similarly, the IC_{50} of all 4 Ras/FGFR3-positive HMCLs (0.4-2.9 μM) were lower than their negative counterparts (4.1-4.6) (Table 1). Primary MM cells from 4 patients at the time of relapse were treated with PKC412 in coculture with patient-derived bone marrow stromal cells (BMSCs). All demonstrated sensitivity to 0.5 μM PKC412 after 72 hours in a fashion similar to the HMCLs (Figure 5C).

Apoptosis induction was confirmed in NCI-H929 and LP-1 when treated with 1 and 3 μM PKC412 for 72 hours as determined by annexin V staining (Figure 1B). Similarly, whole-cell lysates from NCI-H929 and LP-1 demonstrated PARP cleavage at both 24 and 72 hours after PKC412 (Figure 1C). The PepTag assay for nonradioactive detection of PKC demonstrated the expected decrease in PKC activity in all 3 HMCLs tested (NCI-H929, OPM2, and U266) (Figure 1D); however, Western blots demonstrated no apparent correlation between basal PKC expression levels or the pattern of PKC isoform expression and sensitivity to PKC412 (summarized in Table 1). Induction of both p21 and p53 was seen in PKC412-treated HMCLs (data not shown); however, this did not correlate with the level of apoptosis induced, suggesting that PKC412-induced apoptosis is not significantly p53/p21 dependent (data not shown). This is further supported by the efficacy of PKC412 against HMCLs (KMS-11 and U266) that do not express wild-type p53 (data not shown).

**PKC412 induces discordant c-fos and c-jun expression and increased AP-1 activation**

On the basis of the possible association of Ras/FGFR3 positivity with enhanced sensitivity to PKC412, the down-stream mediators of Ras/FGFR3 signaling, c-Fos and c-Jun, were evaluated. To determine the effect of PKC412 on C-FOS expression, HMCLs were stimulated with 100 nM PMA (phorbol 12-myristate 13-acetate) with or without prior PKC412 treatment. Pretreatment with PKC412 inhibited the PMA-induced increase in C-FOS mRNA as determined by RT-PCR (Figure 2A). Similarly, RT-PCR demonstrated down-regulation of basal C-FOS transcription (Figure 2B) that was also associated with reduced c-Fos nuclear protein expression as determined by Western blot (Figure 2C). Conversely, RT-PCR demonstrated that a single dose of PKC412 induced a sustained increase in C-JUN expression maintained for at least 20 hours (Figure 2D) that was associated with an increase in both the expression and phosphorylation of c-Jun protein (data not shown). Subsequently,
using a luciferase assay. AP-1 transcriptional activity was found to increase following PKC412 treatment in both HMCLs tested, NCI-H929 (Figure 2E) and RPMI 8226 (data not shown).

PKC412-induced apoptosis is preceded by the production of reactive oxygen species (ROS) and is partially JNK dependent

The effects of PKC412 on ROS generation were examined. As seen in Figure 3A, PKC412 induced an increase in ROS levels in both NCI-H929 and LP-1 as early as 15 minutes after treatment with PKC412, and the increase was sustained for at least 5 hours. This PKC412-induced increase in ROS production was inhibited by pretreatment with the free radical scavenger LNAC (Figure 3B).

The effects of PKC412 on ROS generation were examined. As seen in Figure 3A, PKC412 induced an increase in ROS levels in both NCI-H929 and LP-1 as early as 15 minutes after treatment with PKC412, and the increase was sustained for at least 5 hours. This PKC412-induced increase in ROS production was inhibited by pretreatment with the free radical scavenger LNAC (Figure 3B). Published data have demonstrated that ROS-induced apoptosis is potentiated by JNK.25,26 In view of this and the observed PKC412-induced up-regulation of C-JUN, we determined whether PKC-induced apoptosis was JNK dependent. Western blots of NCI-H929 and LP-1 whole-cell lysates following 4 μM PKC412 with or without 25 μM of the specific JNK inhibitor SP600125 demonstrated abrogation of both PKC412-induced expression and phosphorylation of c-Jun in the context of JNK inhibition (Figure 3C).

Stress-induced activation of the NFκB pathway and up-regulation of the HSP response may mitigate against drug- and radiation-induced apoptosis.27,28 Inhibition of these induced prosurvival responses may thus theoretically enhance cell killing; therefore, the effect of PKC412 on NFκB and HSP was evaluated. As seen in Figure 4A and B, PKC412 induced significantly increased expression of both HSP70 (Figure 4A) and HSP90 (Figure 4B) compared with untreated controls (P = .023 and .020 for NCI-H929, and P = .023 and .027 for LP-1, respectively). To determine the effect of PKC412 on NFκB, nuclear translocation of NFκB was investigated. Treatment with 1 and 3 μM PKC412 for 72 hours induced a dose-dependent increase in nuclear translocation of NFκB (Figure 4C) with an apparent correlation between HMCL PKC412 sensitivity and the magnitude of PKC412-induced NFκB nuclear translocation: LP-1 (less PKC412 sensitive) 1.7-fold increase versus NCI-H929 (more PKC412 sensitive) 6.5-fold increase (Figure 4C).

Table 1. Ras/FGFR3 status, baseline PKC-c-fos levels, and PKC412 IC50s for HMCLs

<table>
<thead>
<tr>
<th></th>
<th>U266</th>
<th>LP-1</th>
<th>RPMI-8226</th>
<th>OPM2</th>
<th>NCI-H929</th>
<th>KMS-11</th>
</tr>
</thead>
<tbody>
<tr>
<td>PKCα</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>ND</td>
</tr>
<tr>
<td>PKCβ</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>PKCγ</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>ND</td>
</tr>
<tr>
<td>Activating FGFR3 mutation</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Activating RAS mutation</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>ND</td>
<td></td>
</tr>
<tr>
<td>Total PKC expression</td>
<td>+/−</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td>Baseline C-FOS expression</td>
<td>++</td>
<td>+/−</td>
<td>+/−</td>
<td>+++</td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td>PKC412 IC50, μM</td>
<td>4.6</td>
<td>4.1</td>
<td>1</td>
<td>0.75</td>
<td>0.4</td>
<td></td>
</tr>
</tbody>
</table>

Basal PKC and c-fos expression reported as not detected (−), weakly detected (+/−), detected (+), strongly detected (+++), very strongly detected (++++) by Western blot/RT-PCR. PKC412 IC50 was determined using MTS assay (Promega). ND indicates not determined.

HMCLs exhibit prosurvival stress responses following treatment with PKC412

Stress-induced activation of the NFκB pathway and up-regulation of the HSP response may mitigate against drug- and radiation-induced apoptosis.27,28 Inhibition of these induced prosurvival responses may thus theoretically enhance cell killing; therefore, the effect of PKC412 on NFκB and HSP was evaluated. As seen in Figure 4A and B, PKC412 induced significantly increased expression of both HSP70 (Figure 4A) and HSP90 (Figure 4B) compared with untreated controls (P = .023 and .020 for NCI-H929, and P = .023 and .027 for LP-1, respectively). To determine the effect of PKC412 on NFκB, nuclear translocation of NFκB was investigated. Treatment with 1 and 3 μM PKC412 for 72 hours induced a dose-dependent increase in nuclear translocation of NFκB (Figure 4C) with an apparent correlation between HMCL PKC412 sensitivity and the magnitude of PKC412-induced NFκB nuclear translocation: LP-1 (less PKC412 sensitive) 1.7-fold increase versus NCI-H929 (more PKC412 sensitive) 6.5-fold increase (Figure 4C). Increased NFκB transcriptional activation after PKC412 was confirmed using a luciferase assay for both NCI-H929 (Figure 4D) and RPMI 8226 (data not shown).
Pretreatment with PKC412 prior to NFκB inhibition induces synergistic killing of HMCLs and primary MM cells

The feasibility of exploiting the observed PKC412-induced stress-response to enhance MM-cell killing was evaluated. When NCI-H929 or OPM2 cells were treated with a combination of PKC412 and proteasome inhibitor bortezomib, there was greater cell death than with PKC412 alone (Figure 5A). The increment in cell killing with either PKC412 then bortezomib or bortezomib then PKC412 when compared with PKC412 alone was statistically significant for both HMCLs tested (NCI-H929, P < .001 and P < .001; OPM2, P < .001 and P = .029, respectively). However, the PKC412 then bortezomib sequence was clearly superior to bortezomib then PKC412 for both HMCLs (NCI-H929, P = .024; OPM2, P = .013). The calculated SQs for OPM2 for PKC412 then bortezomib or the

Figure 2. PKC412 induces modulation of c-fos and c-jun and increases AP-1 transcriptional activity. (A) RT-PCR of c-FOS following 90-minute pretreatment with PKC412 (10 μM) or DMSO (1:1000) followed by 30 minutes of PMA (100 nM) stimulation. (● indicates LP-1; □, OPM2). Graph represents data from 2 individual experiments. Representative image shown. (B) RT-PCR of C-FOS following PKC412 (10 μM) for 30 minutes, 4 hours, and 20 hours (● indicates NCI-H929). Graph represents data from 2 individual experiments. Representative image shown. For both panels A and B, Scion Image (Scion, Frederick, MD) was used for densitometric analysis. (C) Reduction in nuclear expression of c-fos after 24 hours of treatment with 2 μM and 4 μM PKC412 was determined by Western blot. (D) RT-PCR of C-JUN after PKC412 (10 μM) treatment for 30 minutes, 4 hours, and 20 hours (● indicates NCI-H929). Graph represents data from 2 individual experiments. Representative image is shown. (E) PKC412 (P) (5 μM) treatment induces transcriptional activation of AP-1 as determined by luciferase assay (measured after 18 hours of treatment) (● indicates NCI-H929). Graph represents results from 2 experiments. Error bars for all graphs indicate SEM.

Figure 3. PKC412-induced apoptosis is preceded by the production of ROS and is JNK dependent. (A) Treatment with PKC412 (5 μM) induces ROS production in HMCLs measured by H2DCFDA (1 μg/mL) fluorescence (● indicates NCI-H929; □, LP-1). Graph represents data from 2 individual experiments. (B) PKC412-induced (5 μM for 30 minutes) ROS production was inhibited by 2 hours of pretreatment with LNAC (4 mM) as measured by H2DCFDA (1 μg/mL) fluorescence (● indicates LP-1; D, DMSO; P, PKC412; L, LNAC) (*P = .0014 versus PKC412 treatment, Student t test). Graph represents data from 3 individual experiments. (C) PKC412-induced (3 hours of treatment) modulation of c-jun and phosphorylation c-jun in HMCLs with and without pretreatment with the JNK-specific inhibitor SP600125 as shown by Western blot (P indicates PKC412; S, SP600125; D, DMSO). Representative image from 1 of 3 individual experiments is shown. (D) PKC412-induced apoptosis (4 μM PKC412) after 72 hours is partially abrogated by 30 minutes of pretreatment with SP600125 (25 μM) as determined by annexin V–FITC/PI flow cytometry of NCI-H929 (●) and LP-1 (□). (*P = .027 and .043, respectively, versus PKC412 treatment alone, Student t test). Graph represents data from 3 individual experiments). Error bars for all graphs indicate SEM.
reverse order were 3.5 and 1.6, respectively. This is consistent with both combinations demonstrating synergy, but with PKC412 pretreatment prior to bortezomib demonstrating markedly greater synergy than the reverse order of administration. To determine whether the increase in cell death induced by cotreatment with bortezomib was in part secondary to NFκB inhibition,\textsuperscript{29} we cotreated HMCLs (NCI-H929 and LP-1) with PKC412 and the NFκB inhibitor SN50. Greater killing was seen when cells were treated with a combination of PKC412 and SN50 than with either compound alone, although this was less than that seen with the bortezomib combination, likely because of the latter’s broader range of action than SN50 (Figure 5B). Again the sequence using PKC412 first was superior in both cases. Similarly, treatment of all 4 primary MM samples demonstrated superior cell killing when using the same sequence of drug administration (Figure 5C). Importantly, the derived SQs for the PKC412 then bortezomib treatment of the primary MM cells were consistent with either synergistic or additive cell killing (MM016 SQ 2.0; MM021 SQ 1.6; and MM022 SQ = 1.0).

**Discussion**

PKC412 is an orally bioavailable staurosporine derivative capable of inhibiting a range of kinases\textsuperscript{14,29} and has demonstrated safety in completed phase 1 trials.\textsuperscript{30,31} We have demonstrated that PKC412 exerts an antiproliferative and apoptosis-inducing effect on both HMCLs and primary MM cells at doses of at least 0.5 μM. The activity of PKC412 in this context was associated with ROS generation, down-regulation of C-FOS, sustained up-regulation of phosphorlated c-Jun, and increased AP-1 transcriptional activity. Both sustained activation of c-Jun and apoptosis could be significantly abrogated by JNK inhibition. Finally, PKC412 treatment of HMCLs was associated with secondary prosurvival stress responses characterized by significant activation of NFκB signaling and elevations of HSP70 and HSP90. Targeting of the former with NFκB inhibitors in combination with PKC412 led to synergistic killing of both HMCLs and primary MM cells.

Examination of the HMCL responses demonstrated that the 4 Ras/FGFR3-positive HMCLs were more susceptible to PKC412 than the Ras/FGFR3-negative HMCLs (Figure 1). All exhibited lower IC\textsubscript{50}s and in 3 of the 4 positive HMCLs the IC\textsubscript{50}s were 4.5- to 11.5-fold lower than those of their Ras/FGFR3-negative counterparts (Table 1). Likewise, all the positive HMCLs demonstrated a statistically greater magnitude of cell killing at the 5-μM PKC412 dosing level than the negative HMCLs. Consistent with our observations, a study by Chen et al\textsuperscript{11} showed that the IC\textsubscript{50} for PKC412 was lower for t(4;14) MM cell lines that overexpress mutant FGFR3 than for those that do not.

Activating RAS and FGFR3 mutations are mutually exclusive in MM,\textsuperscript{32} suggesting a Ras-like role for FGFR3 in MM survival, proliferation, and tumor progression.\textsuperscript{25} and recent insights into the role of c-Fos, c-Jun, and JNK in Ras signaling provide a possible basis for the enhanced sensitivity of the Ras/FGFR3-positive HMCLs to PKC412. Kang et al\textsuperscript{13} reported that H-RAS–transformed human breast epithelial cells undergo apoptosis on caspase exposure in contrast to nontransformed counterparts.\textsuperscript{28} Furthermore, capsaicin-induced apoptosis was mediated by modulation of Ras-downstream signaling molecules, including JNK activation. They were able to conclude that the presence of Ras enabled the selective killing of the transformed cells by caspase. Similarly, Xiao and Lang\textsuperscript{34} reported that the JNK/c-Jun/AP-1 pathway mediates oncogenic Ras function in lung carcinoma cells, whereas Wang et al\textsuperscript{35} have demonstrated a requirement for Ras for full activation of JNK by microtubule-interfering agents such as paclitaxel and vinblastine, again consistent with Ras-mediated sensitization to drug effects. Importantly, evidence suggests that sustained activation of JNK, as was seen in HMCLs secondary to PKC412
Figure 5. Synergistic killing induced by PKC412 and NFκB inhibition is schedule dependent. (A) Cotreatment with bortezomib (B) (8 nM) and PKC412 (P) (0.5 μM) enhances killing of HMCLs (● indicates NCI-H929; ■, LP-1) at 72 hours as measured by MTS assay. Graph represents data from 3 individual experiments. Combination treatments were 6 hours P pretreatment then B [P then B] or 6 hours B pretreatment then P [B then P]. NCI-H929, *P < .0015 [P then B] and .001 [B then P], respectively, versus PKC412 alone; OPM2, *P < .001 [P then B] and 0.029 [B then P], respectively, versus PKC412 alone. NCI-H929, *P < .001 [P then B] versus [B then P]; OPM2, *P < .013 [P then B] versus [B then P], Student t test. OPM2 SQ = 3.5 for [P then B] versus PKC412 alone and SQ = 1.8 for [B then P] versus PKC412 alone. (B) Cotreatment with SN50 (S) (25 μg/mL) and PKC412 (P) (1 μM) enhances killing of HMCLs (● indicates NCI-H929; ■, LP-1). Graph represents data from 3 individual experiments. (C) Seventy-two hours of treatment with PKC412 (0.5 μM) induces apoptosis in primary MM cells, and killing was enhanced by co pretreatment with bortezomib (8 nM) (● indicates patient MM016; ■, patient MM017; ■, patient MM021; and □, patient MM022). SQs for [P then B] were 1.0, 2.0, 1.6, and 1.0, respectively. Error bars for all graphs indicate SEM.

Treatment, can initiate the apoptotic process, whereas transient JNK activation may have a role in cell proliferation.36 Finally, it has been reported that up-regulation of c-Fos by Ras is an important downstream mediator of the proliferative effects of Ras,37 and recent data have demonstrated a critical role for c-Fos in the survival of transformed cells.22

These observations combined with our data are consistent with PKC412-induced apoptosis of HMCLs being, at least in part, secondary to modulation of c-Fos and c-Jun signaling downstream of Ras. The enhanced sensitivity of Ras/FGFR3-positive HMCLs, despite similar magnitudes of signaling changes in the Ras/FGFR3-negative HMCLs, would be explained by the greater reliance of the Ras/FGFR3-positive HMCLs on the integrity of Ras/FGFR3 downstream signaling in contrast to the negative HMCLs, where such pathways may not serve a critical function in terms of cell survival and proliferation (e.g., IL-6-dependent HMCL U266). Thus, despite the pleiotropic nature of PKC412-induced cellular changes, the interference with downstream components of the Ras/FGFR3 pathway may provide the basis for our observations and provides a rationale for the investigation of PKC412-targeted therapy of Ras/FGFR3-positive MM.

ROS production has been shown to have a role in stress signaling by potentiating JNK activation25,26,38; however, coincident prosurvival NFκB activation may abrogate apoptosis induction as shown in work evaluating the potential of histone deacetylase inhibition as a therapeutic strategy in BCR-ABL-positive leukemias.27 Despite the recognized role of PKC activation in the up-regulation of NFκB signaling,39 the overall effect of HMCL exposure to PKC412 was marked enhancement of NFκB activation (1.7- to 6.5-fold increase), again reflecting the pleiotropic effect of PKC412 treatment. Further evidence of a significant stress response was the significant elevation of both HSP70 and HSP90 within 24 hours of PKC412 exposure. Therefore, strategies capable of effectively inhibiting this secondary prosurvival stress response should enhance PKC412-cell killing. This was clearly shown by combining PKC412 with bortezomib and recapitulated by combination studies with the specific NFκB inhibitor SN50. Importantly, the PKC412-bortezomib combination induced synergistic killing of not only HMCLs but also primary MM cells in BMSC cultures. These data are consistent with observations from Chunrong et al,47 who showed that the NFκB inhibitor Bay 11-7082 was able to reproduce bortezomib’s ability to potentiate SAHA lethality in the K562 chronic myelocytic leukemia cell line.

We also showed that in both HMCLs and primary MM cells the magnitude of killing was greatest with PKC412 pretreatment prior to NFκB inhibition, rather than the reverse order, highlighting the importance of sequence of drug administration. Similarly, Mit-siades et al48 have reported that when the HMCL MM.1S was pretreated with doxorubicin for 24 hours prior to the addition of bortezomib, greater cell killing was seen than with the reverse sequence. Likewise, Fahy et al49 reported that the sequence of administration when using gemcitabine and bortezomib was crucial, with enhanced killing of pancreatic cancer cells occurring with gemcitabine followed by bortezomib. Although we have not attempted to fully optimize the scheduling and dosing of PKC412 and NFκB inhibition, we have provided a framework for such an evaluation to be performed. Furthermore, the demonstration of an HSP stress response subsequent to PKC412 treatment provides a rationale for the exploration of PKC412 and HSP inhibitor combination approaches. The latter, at least theoretically, is particularly attractive in view of the demonstrable preclinical activity of single-agent HSP inhibition against MM.52

In conclusion, we have demonstrated that PKC412 demonstrates activity against a range of genetically heterogenous HMCLs and primary MM cells and that this process is largely mediated by JNK. Furthermore, PKC412 provokes a marked prosurvival stress response. This provides the basis for rationally selected potential therapeutic combinations as demonstrated by the synergistic killing of MM cells by sequential exposure to PKC412 and NFκB inhibition. These data provide a rationale for the clinical evaluation of PKC412 both as a single agent and in combination with other available novel targeted therapeutics.

Acknowledgement

We would like to thank Mrs Karly Sourris for help with flow cytometry.

Authorship

Contribution: J.S. participated in designing and performing the research, analyzed the data, and wrote the paper; T.K. participated in performing the research; A.S. designed the research, analyzed
PKC412 INDUCES JNK-DEPENDENT APOPTOSIS

1719

Correspondence: Andrew Spencer, Myeloma Research Group, Ground Floor, South Block, Alfred Hospital, Commercial Rd, Melbourne VIC 3004, Australia; e-mail: aspencer@netpace.net.au.

References


PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells

Janelle Sharkey, Tiffany Khong and Andrew Spencer